Resident's Forum
RF-The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis
FR-Estudio METOP: nuevas evidencias sobre el uso del metotrexato subcutáneo en psoriasis
D. Morgado-Carrasco, X. Fustà-Novell, J. Riera-Monroig, J.M. Mascaró Galy
Corresponding author
Dermatology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Read
5178
Timeswas read the article
1942
Total PDF
3236
Total HTML
Share statistics
array:23 [ "pii" => "S1578219017302688" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.08.012" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1677" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2017;108:865-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 321 "formatos" => array:3 [ "EPUB" => 21 "HTML" => 200 "PDF" => 100 ] ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S0001731017302090" "issn" => "00017310" "doi" => "10.1016/j.ad.2017.04.007" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1677" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2017;108:865-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 213 "formatos" => array:2 [ "HTML" => 149 "PDF" => 64 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de residentes</span>" "titulo" => "FR-Estudio METOP: nuevas evidencias sobre el uso del metotrexato subcutáneo en psoriasis" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "865" "paginaFinal" => "866" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell, J. Riera Monroig, J.M. Mascaró Galy" "autores" => array:4 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Riera Monroig" ] 3 => array:2 [ "nombre" => "J.M." "apellidos" => "Mascaró Galy" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219017302688" "doi" => "10.1016/j.adengl.2017.08.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302688?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017302090?idApp=UINPBA000044" "url" => "/00017310/0000010800000009/v1_201711021011/S0001731017302090/v1_201711021011/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219017302731" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.08.015" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1686" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:867-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 352 "formatos" => array:3 [ "EPUB" => 23 "HTML" => 254 "PDF" => 75 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Videos of Surgical Procedures in Dermatology</span>" "titulo" => "The Single-Stage Paramedian Forehead Flap" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "867" "paginaFinal" => "868" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Colgajo paramedial frontal en un tiempo quirúrgico" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Martinez-Lopez, I. Perez-Lopez, E. Garcia-Dura, J. Tercedor-Sanchez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Martinez-Lopez" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Perez-Lopez" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Garcia-Dura" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Tercedor-Sanchez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017302399" "doi" => "10.1016/j.ad.2017.04.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017302399?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302731?idApp=UINPBA000044" "url" => "/15782190/0000010800000009/v1_201711021004/S1578219017302731/v1_201711021004/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219017302767" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.08.017" "estado" => "S300" "fechaPublicacion" => "2017-11-01" "aid" => "1665" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:863-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 380 "formatos" => array:3 [ "EPUB" => 23 "HTML" => 273 "PDF" => 84 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Practical Dermoscopy</span>" "titulo" => "Dermoscopic Features of Facial Trichilemmoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "863" "paginaFinal" => "864" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Características dermatoscópicas del triquilemoma facial" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 742 "Ancho" => 990 "Tamanyo" => 240394 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Histological image (hematoxylin and eosin, x8). A well-defined neoplastic proliferation was observed in the superficial dermis, in contact with the epidermis. It was made up of squamous cells, some with vacuolization, with foci of keratinization and corneal microcysts. Note the ulcerated epidermis and dilated vessels in the tumor periphery (arrows).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. Lozano-Masdemont, I.M. de Lara Simón, L. González López" "autores" => array:3 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "Lozano-Masdemont" ] 1 => array:2 [ "nombre" => "I.M. de" "apellidos" => "Lara Simón" ] 2 => array:2 [ "nombre" => "L. González" "apellidos" => "López" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101730193X" "doi" => "10.1016/j.ad.2017.03.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101730193X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302767?idApp=UINPBA000044" "url" => "/15782190/0000010800000009/v1_201711021004/S1578219017302767/v1_201711021004/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => "RF-The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "865" "paginaFinal" => "866" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell, J. Riera-Monroig, J.M. Mascaró Galy" "autores" => array:4 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Riera-Monroig" ] 3 => array:4 [ "nombre" => "J.M." "apellidos" => "Mascaró Galy" "email" => array:1 [ 0 => "josemanuel.mascaro@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Dermatology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Estudio METOP: nuevas evidencias sobre el uso del metotrexato subcutáneo en psoriasis" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Methotrexate (MTX) has been a first-line treatment for psoriasis for half a century. However, little high-quality scientific evidence and few well-designed clinical trials have yet been performed to support its efficacy. A recent meta-analysis showed a 75% reduction in the baseline Psoriasis Area Severity Index (PASI75) at 12 to 16 weeks in 45% of patients, and side effects that required drug withdrawal in 6.9%.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> A clinical trial of briakinumab versus MTX found that only 23.9% of patients receiving MTX achieved a PASI75 at 52 weeks, and that 72% (118/163) discontinued the drug due to lack of efficacy (95/163), side effects (9/163), or other reasons.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Regarding the route of administration, some studies in rheumatoid arthritis suggest greater efficacy of methotrexate when given by subcutaneous injection (MTXSC).<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Warren et al.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> recently published the results of the European METOP study, a multicenter randomized, double-blind clinical trial of MTXSC versus placebo in patients with moderate to severe plaque psoriasis (PASI<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>10). During the first 16 weeks, patients received placebo (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>29) or MTXSC (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>91) at a dose of 17.5<span class="elsevierStyleHsp" style=""></span>mg/week, increasing to 22.5<span class="elsevierStyleHsp" style=""></span>mg/week depending on the clinical response at week 8. Subsequently, all patients received MTXSC up to week 52. At week 16, 41% of the MTXSC group and 10% of the placebo group achieved PASI75 (relative risk: 3.93; 95% confidence interval, 1.31-11.81; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.0026). At week 52, 45% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>41) of patients had achieved a PASI75, and 28% a PASI90. MTXSC was well tolerated, with no reports of death, serious infections, or major cardiovascular events. Of the patients who received the drug for 52 weeks, 3% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3) presented gastrointestinal intolerance requiring treatment discontinuation. Biopsies were performed on 27 patients prior to treatment and during week 16, observing a marked reduction in interleukin 17 and interferon-γ mRNA levels in those individuals with MTXSC who achieved a PASI75.</p><p id="par0015" class="elsevierStylePara elsevierViewall">These results after 12 to 16 weeks of treatment with MTXSC are similar to those observed previously with oral MTX,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> with a PASI75 of around 40%. However, at week 52, the subcutaneous route appears to be considerably superior, with a PASI75 of 45% compared to 23% with oral MTX in previous studies, and a lower rate of treatment interruption.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Furthermore, a PASI75 of 27% was achieved at 8 weeks in the METOP study compared with only 20% in a clinical trial with oral MTX.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> This would suggest a more rapid clinical response with MTXSC. That study also supported the use of a higher starting dose of MTXSC, as has recently been proposed.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Although MTX does not show the efficacy of the latest-generation biologic agents, it does have an appreciable response rate, a good safety profile, and lower cost. The subcutaneous route would appear to have advantages over oral MTX and could be considered as first-line therapy in psoriasis, although high-quality clinical trials comparing the efficacy of oral vs subcutaneous MTX are still required in this disease.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec908582" "palabras" => array:4 [ 0 => "Methotrexate" 1 => "Subcutaneous" 2 => "Psoriasis" 3 => "Metop" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Morgado-Carrasco D, Fustà-Novell X, Riera Monroig J, Mascaró Galy JM. RF-The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis. Actas Dermosifiliogr. 2017;108:865–866.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. West" 1 => "S. Ogston" 2 => "J. Foerster" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0153740" "Revista" => array:5 [ "tituloSerie" => "PLoS One" "fecha" => "2016" "volumen" => "11" "paginaInicial" => "e0153740" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27168193" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Reich" 1 => "R.G. Langley" 2 => "K.A. Papp" 3 => "J.P. Ortonne" 4 => "K. Unnebrink" 5 => "M. Kaul" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1010858" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2011" "volumen" => "365" "paginaInicial" => "1586" "paginaFinal" => "1596" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22029980" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "MC-MTX.6/RH Study Group" "etal" => true "autores" => array:6 [ 0 => "J. Braun" 1 => "P. Kästner" 2 => "P. Flaxenberg" 3 => "J. Währisch" 4 => "P. Hanke" 5 => "W. Demary" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23144" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "73" "paginaFinal" => "81" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18163521" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.B. Warren" 1 => "U. Mrowietz" 2 => "R. von Kiedrowski" 3 => "J. Niesmann" 4 => "D. Wilsmann-Theis" 5 => "K. Ghoreschi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(16)32127-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "389" "paginaInicial" => "528" "paginaFinal" => "537" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28012564" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metotrexato en psoriasis moderada-grave revisión de la literatura y recomendaciones de experto" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Carrascosa" 1 => "P. de la Cueva" 2 => "M. Ara" 3 => "L. Puig" 4 => "X. Bordas" 5 => "G. Carretero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2015.10.005" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2016" "volumen" => "107" "paginaInicial" => "194" "paginaFinal" => "206" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26614486" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010800000009/v1_201711021004/S1578219017302688/v1_201711021004/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000009/v1_201711021004/S1578219017302688/v1_201711021004/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302688?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 6 | 13 |
| 2024 October | 67 | 42 | 109 |
| 2024 September | 75 | 23 | 98 |
| 2024 August | 97 | 62 | 159 |
| 2024 July | 80 | 32 | 112 |
| 2024 June | 421 | 40 | 461 |
| 2024 May | 58 | 30 | 88 |
| 2024 April | 71 | 23 | 94 |
| 2024 March | 76 | 27 | 103 |
| 2024 February | 50 | 29 | 79 |
| 2024 January | 49 | 28 | 77 |
| 2023 December | 46 | 16 | 62 |
| 2023 November | 56 | 27 | 83 |
| 2023 October | 51 | 19 | 70 |
| 2023 September | 57 | 30 | 87 |
| 2023 August | 34 | 14 | 48 |
| 2023 July | 57 | 27 | 84 |
| 2023 June | 53 | 22 | 75 |
| 2023 May | 38 | 26 | 64 |
| 2023 April | 38 | 17 | 55 |
| 2023 March | 61 | 34 | 95 |
| 2023 February | 51 | 19 | 70 |
| 2023 January | 49 | 34 | 83 |
| 2022 December | 64 | 31 | 95 |
| 2022 November | 44 | 34 | 78 |
| 2022 October | 31 | 19 | 50 |
| 2022 September | 51 | 33 | 84 |
| 2022 August | 51 | 31 | 82 |
| 2022 July | 54 | 43 | 97 |
| 2022 June | 24 | 22 | 46 |
| 2022 May | 32 | 45 | 77 |
| 2022 April | 42 | 34 | 76 |
| 2022 March | 49 | 60 | 109 |
| 2022 February | 37 | 44 | 81 |
| 2022 January | 48 | 43 | 91 |
| 2021 December | 31 | 51 | 82 |
| 2021 November | 60 | 52 | 112 |
| 2021 October | 53 | 67 | 120 |
| 2021 September | 37 | 43 | 80 |
| 2021 August | 46 | 41 | 87 |
| 2021 July | 30 | 26 | 56 |
| 2021 June | 26 | 33 | 59 |
| 2021 May | 36 | 48 | 84 |
| 2021 April | 78 | 111 | 189 |
| 2021 March | 67 | 32 | 99 |
| 2021 February | 63 | 34 | 97 |
| 2021 January | 43 | 27 | 70 |
| 2020 December | 34 | 20 | 54 |
| 2020 November | 43 | 28 | 71 |
| 2020 October | 43 | 23 | 66 |
| 2020 September | 28 | 15 | 43 |
| 2020 August | 33 | 26 | 59 |
| 2020 July | 28 | 22 | 50 |
| 2020 June | 27 | 29 | 56 |
| 2020 May | 17 | 13 | 30 |
| 2020 April | 22 | 19 | 41 |
| 2020 March | 21 | 16 | 37 |
| 2020 February | 3 | 0 | 3 |
| 2019 December | 2 | 0 | 2 |
| 2019 September | 4 | 0 | 4 |
| 2019 June | 2 | 0 | 2 |
| 2019 March | 2 | 0 | 2 |
| 2019 February | 2 | 0 | 2 |
| 2019 January | 1 | 0 | 1 |
| 2018 December | 3 | 0 | 3 |
| 2018 November | 1 | 0 | 1 |
| 2018 October | 11 | 0 | 11 |
| 2018 September | 6 | 0 | 6 |
| 2018 March | 0 | 1 | 1 |
| 2018 February | 20 | 4 | 24 |
| 2018 January | 33 | 12 | 45 |
| 2017 December | 41 | 14 | 55 |
| 2017 November | 64 | 39 | 103 |
| 2017 October | 2 | 16 | 18 |
| 2017 September | 4 | 14 | 18 |
Show all
